UNSPSC 51401544: Pivoxazepam

This classification denotes an anxiolytic with the molecular formula C20H19ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4ER8Z6Q3U, chemically known as 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepin-2-one pivalate (ester) but generally known as pivoxazepam, which bears US NIH Compound Identifier 68722. European Medicines Agency schedules Pivoxazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09953MIG.

UNSPSC 51401544 Pivoxazepam, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—solicits Naloxone and Safe Drug Deactivation Systems, which fall outside the scope of the benzodiazepine Pivoxazepam. The mismatch suggests either a classification error in the source data or a temporary miscoding by the issuing body. State and local procurement offices do not appear to be actively sourcing Pivoxazepam under this code at present.

The Seminole County opportunity itself targets community health initiatives, requiring annual delivery of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly shipments to the Seminole County Community Health Building in Sanford, Florida. Vendors must submit electronic bids by July 26, 2023, include all shipping and delivery costs, maintain workers' compensation and commercial general liability insurance, and comply with drug-free workplace and E-Verify requirements. The contract carries an initial two-year term with a one-year renewal option and a three-month probationary period. Given the narrow activity record and the category-mismatch issue, this code presents minimal procurement signal for business development purposes at this time.